Genetic determinants of the humoral immune response in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 28, 2020
- Accepted in final form May 26, 2020
- First Published July 16, 2020.
Author Disclosures
- Christiane Gasperi, MD,
- Till F.M. Andlauer, PhD,
- Ana Keating, MSc,
- Benjamin Knier, MD,
- Ana Klein, MD,
- Verena Pernpeintner, MD,
- Peter Lichtner, PhD,
- Ralf Gold, MD,
- Frauke Zipp, MD,
- Florian Then Bergh, MD,
- Martin Stangel, MD,
- Hayrettin Tumani, MD,
- Brigitte Wildemann, MD,
- Heinz Wiendl, MD,
- Antonios Bayas, MD,
- Tania Kümpfel, MD,
- Uwe K. Zettl, MD,
- Ralf A. Linker, MD,
- Ulf Ziemann, MD,
- Matthias Knop, MD,
- Clemens Warnke, MD,
- Manuel A. Friese, MD,
- Friedemann Paul, MD,
- Björn Tackenberg, MD,
- Achim Berthele, MD and
- Bernhard Hemmer, MD
- Christiane Gasperi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Deutsche Forschungsgemeinschaft (DFG) - 6-month research fellowship (grant number GA 2913/1-1)
NONE
NONE
NONE
NONE
NONE
NONE
- Till F.M. Andlauer, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
My salary was paid by the Max Planck Institute of Psychiatry and, subsequently, the Klinikum rechts der Isar, using third party funding by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent, under the auspices of the e:Med Programme (grant 01ZX1614J) and through the DIFUTURE consortium of the Medical Informatics Initiative Germany (grant 01ZZ1804A), and by the European UnionÂs Horizon 2020 Research and Innovation Programme (grant MultipleMS, EU RIA 733161). None of these grants were awarded directly to me.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ana Keating, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Benjamin Knier, MD,
NONE
NONE
(1) Bayer, Travel Compensation (2) Merck Serono, Travel Compensation (3) ECTRIMS (non-profit), travel grant (4) Neurowind e.V. (non-profit), travel grant (5) Novartis, Travel Compensation
Frontiers in Neurology, Review Editor, 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Kompetenznetz Multiple Sklerose (KKNMS), research grant from the Bundesministerium für Bildung und Forschung
Kommission für Klinische Foschung (KKF), intramural research grant within the Technical University of Munich
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ana Klein, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Verena Pernpeintner, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter Lichtner, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf Gold, MD,
(1) TEVA Laquinimod DSMB AbbVie
NONE
Speaker honoraria from Biogen, Genzyme, TEVA, Merckserono, BayerSchering,Celgene, Novartis
SAGE Journal TAND, Experimental Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
From Roche From Merck From Bayer
NONE
NONE
NONE
NONE
NONE
- Frauke Zipp, MD,
(1) MPG (2) Merck Serono (3) Roche Novartis (4) Sanofi-Aventis (5) Celgene (6) ONO (7) Octapharma
NONE
(1) MPG (2) Merck Serono (3) Roche Novartis (4) Sanofi-Aventis (5) Celgene (6) ONO (7) Octapharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Genzyme
(1) DFG CRC-TRR 128, Co-Spokesperson/Spokesperson, 2012-2020 (2) DFG CRC1080, PI, 2013-2020 (3) BMBF KKNMS, PI, 2013-2019
NONE
(1) Progressive MS Alliance, BRAVEinMS
NONE
NONE
NONE
NONE
NONE
NONE
- Florian Then Bergh, MD,
Speaker honoraria and consultancy fees as a speaker and advisor from Actelion, Bayer Healthcare, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA.
NONE
Support to attend scientific meetings from Bayer Schering, Biogen, Merck, Novartis and Sanofi-Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Support for investigator-initiated trials from Actelion, Novartis. Travel support to attend scientific meetings, through the employing institution, from Bayer Schering, Biogen, Merck, Novartis and Sanofi Genzyme.
German Federal Ministry of Research; Deutsche Forschungsgemeinschaft (DFG, federal research funding agency)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Stangel, MD,
Alexion, Biogen, Bayer Healthcare, Baxalta/Shire/Takeda, Celgene, CSL Behring, Grifols, Janssen, MedDay, Merck- Serono, Novartis, Roche, Sanofi-Genzyme
NONE
Travel and speaker honoraria from Bayer Healthcare, Biogen, CSL Behring, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and Teva
PLoS ONE, Academic Editor; Multiple Sclerosis International, Editorial Board Member
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, Merck-Serono, Novartis, Sanofi-Genzyme
Deutsche Forschungsgemeinschaft (DFG), Bundesministerium für Bildung und Forschung (BMBF), EU FP7
NONE
Volkswagenstiftung
NONE
NONE
NONE
NONE
NONE
NONE
- Hayrettin Tumani, MD,
Biogen Idec, Siemens Health, Teva Pharma, Roche, Merck.
NONE
Merck-Serono, AAN participation, 2009 TEVA, ECTRIMS participation, 2008 Biogen, ENS participation, 2009, 2010 TEVA, ENS participation, 2011 Novartis, INS participation 2013 Merck Serono, ECTRIMS participation 2013 Novartis,ENS participation 2014
Neurology, Psychiatry and Brain Research (section editor) since 2011
NONE
NONE
Several industries (Merck-Serono, Bayer, TEVA, Biogen) educational presentations, 2018-2000
NONE
NONE
NONE
NONE
Merck, Teva, Novartis, Sanofi Genzyme, Siemens Health, Biogen, Roche Diagnostics.
BMBF (KKNMS-Project) 2015-2017 DMSG 2018-2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brigitte Wildemann, MD,
Brigitte Wildemann served on scientific advisory boards for Novartis, Sanofi Genzyme, Roche
NONE
Brigitte Wildemann has received personal fees from Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, and Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Brigitte Wildemann reports grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Forschung und Technologie, grants from Dietmar Hopp Stiftung, grants from Klaus Tschira Stiftung, grants from Merck Serono, Novartis Pharmaceuticals, and from Sanofi Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD,
(1) Biogen, (2) Evgen (3) MedDay Pharmaceuticals (4) Merck Serono (5) Novartis (6) Roche Pharma AG (7) Sanofi-Genzyme
NONE
(1) Alexion (2) Biogen (3) Cognomed (4) F. Hoffmann-La Roche Ltd. (5) Gemeinnützige Hertie-Stiftung (6) Merck Serono (7) Novartis (8) Roche Pharma AG (9) Sanofi-Genzyme (10) TEVA (11) WebMD Global
(1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery
NONE
NONE
NONE
(1) Abbvie (2) Actelion (3) Argenx (4) Biogen (5) EMD (3) IGES (4) Johnson & Johnson (5) Merck (6) Novartis (7) Roche (8) Sanofi-Genzyme (9) Swiss Multiple Sclerosis Society (10)UCB
NONE
NONE
NONE
(1) Bayer Healthcare (2) Bayer Vital (3) Biogen (4) Merck Serono (5) Novartis (6) Sanofi  Genzyme (7) Sanofi US (8) TEVA Pharma
(1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020
NONE
(1) Else Kröner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE ChildrenÂs Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Antonios Bayas, MD,
(1) Merck Serono (2) Biogen (3) Novartis (4) TEVA (5) Sanofi/Genzyme (6) Roche (7) Alexion (8) Celgene (9) Bayer Vital
NONE
(1) Merck Serono: travel, speaker honoraria (2) Biogen: travel, speaker honoraria (3) Novartis: travel, speaker honoraria (4) TEVA: travel, speaker honoraria (5) Sanofi/Genzyme: travel, speaker honoraria (6) Roche: speaker honoraria (7) Alexion: speaker honoraria (8) Celgene: travel, speaker honoraria (9) Bayer Vital: speaker honoraria
NONE
NONE
NONE
NONE
(1) Merck Serono (2) Biogen (3) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tania Kümpfel, MD,
T. Kümpfel has served on advisory boards for Roche Pharma
NONE
T. Kümpfel has received speaker honoraria from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, Roche Pharma and Biogen as well as grant support from Novartis and Chugai Pharma in the past.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Uwe K. Zettl, MD,
NONE
NONE
Travel compensation for research meetings: (1) Aventis (2) Bayer (3) Biogen (4) Celgene Speakers fee: (1) Almirall (2) Alexion (3) Bayer (4) Biogen (5) Merck (6) Novartis (7) Roche (8) Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf A. Linker, MD,
Biogen, Celgene, Genzyme, Merck,Novartis, Roche.
NONE
Biogen, Celgene, Genzyme, Merck, Novartis, Roche.
NONE
NONE
NONE
NONE
Biogen, Novartis, Roche.
NONE
NONE
NONE
Biogen, Novartis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ulf Ziemann, MD,
(1) CorTec GmbH
NONE
(1) Bayer Vital GmbH, speaker honorarium (2) Biogen Idec GmbH, speaker honorarium (3) Bristol Myers Squibb GmbH, speaker honorarium (4) Medtronic GmbH, speaker honorarium (5) Pfizer Pharma GmbH, speaker honorarium
(1) Clinical Neurophysiology, Editor-in-Chief, 4 years (2) Journal of Neuroscience, Associate Editor, 5 years (3) Brain Stimulation, Deputy Editor, 12 years (4) Experimental Brain Research, Editorial advisory board member, 15 years
NONE
(1) Lehrbuch Neurologie (2nd edition), Elsevier, 2016 (2) Das TMS Buch, Springer, 2007 (3) The Oxford Handbook of Trancranial Stimulation, Oxford University Press, 2007
NONE
NONE
NONE
(1) Biogen Idec GmbH, Investigator initiated trial (2) Janssen Pharmaceuticals NV, Investigator initiated trial (3) Servier, Investigator initiated trial
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Matthias Knop, MD,
(1) Biogen (2) Genzyme (3) Roche (4) Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Clemens Warnke, MD,
Biogen, Novartis, Roche; institutional fees only.
NONE
Speakers honoraria Novartis, Biogen, Bayer, Genzyme, Alexion. Institutional fees only.
Frontiers in Neurology, associate editor, 2016-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Speakers honoraria payed to the institution: Novartis, Biogen, Roche.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Manuel A. Friese, MD,
NONE
NONE
MAF received honoraria for consultation and travel expenses from Biogen, Merck KGaA, Novartis and Roche unrelated to this work.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Research Foundation, German Ministry of Education and Research
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD,
Novartis OCTIMS study steering committee MedImmune / Viela Bio steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, Celgene
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- Björn Tackenberg, MD,
Commercial(1) CSL Behring(2) Grifols(3) Biogen(4) Novartis(5) Bayer Healthcare(6) Genzyme(7) UCB(8) Roche(9) GILEAD
NONE
Commercial, speaker honoraria(1) CSL Behring(2) Grifols(3) Octapharma(3) Biogen(4) Novartis(5) Bayer Healthcare(6) Genzyme(7) Roche
NONE
NONE
NONE
F. Hoffmann-La Roche AG, Basel, Switzerland
Commercial, Consultancy fees(1) CSL Behring(2) Grifols(3) Biogen(4) Novartis(5) Bayer Healthcare(6) Genzyme(7) UCB(8) Roche(9) GILEAD
NONE
NONE
NONE
Commercial(1) Biogen(2) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
F. Hofmann-La Roche AG Basel
NONE
- Achim Berthele, MD and
NONE
NONE
I received funding for travel and speaker honoraria from Alexion, Bayer Healthcare, Biogen, Genzyme, Merck Serono, Mylan,Novartis, Roche and Teva.
NONE
NONE
NONE
NONE
I have received consultancies from Alexion, Bayer Healthcare, Biogen, Celgene and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bernhard Hemmer, MD
Advisory Boards for Novartis, he has served as DMSC member for AllergyCare, TG Therapeutics and Polpharma Biologics
Me or my institution have received speaker honoraria from Desitin
Excemed
Editorial board member of Jama Neurology, Experimental Neurology and Multiple sclerosis Journal
I hold part of two patents; one for the detection of antibodies and T cells against KIR4.1 in a subpopulati on of MS patients and one for genetic determinants of neutralizing antibodies to interferon β
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Competence Network for Multiple Sclerosis Synergy Excellence Cluster German Research Foundation Bundesministerium für Bildung und Forschung
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (C.G., T.F.M.A., A. Keating, B.K., A. Klein, V.P., A. Berthele, B.H.), Klinikum rechts der Isar, School of Medicine, Technical University of Munich; Institute of Human Genetics (P.L.), Helmholtz Zentrum München, Neuherberg; Department of Neurology (R.G.), St. Josef Hospital, Ruhr-University Bochum; Department of Neurology, Focus Program Translational Neurosciences (FTN) and Research Center for Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2) (F.Z.), University Medical Center of the Johannes Gutenberg University Mainz; Department of Neurology and Translational Center for Regenerative Medicine (F.T.B.), University of Leipzig; Clinical Neuroimmunology and Neurochemistry (M.S.), Department of Neurology, Hannover Medical School, Hannover; Department of Neurology (H.T.), University of Ulm; Clinic of Neurology Dietenbronn (H.T.), Schwendi; Department of Neurology (B.W.), University Hospital Heidelberg; Department of Neurology (H.W.), University of Münster; Department of Neurology (A. Bayas), University Hospital Augsburg; Institute of Clinical Neuroimmunology (T.K.), University Hospital and Biomedical Center, Ludwig-Maximilians University Munich; Department of Neurology (U.K.Z.), Neuroimmunological Section, University of Rostock; Department of Neurology (R.A.L.), University Hospital Erlangen; Department of Neurology (R.A.L.), University of Regensburg; Department of Neurology & Stroke and Hertie-Institute for Clinical Brain Research (U.Z.), Eberhard-Karls-Universität Tübingen; Max Planck Institute of Psychiatry (M.K.), Munich; Department of Neurology (C.W.), Medical Faculty, Heinrich Heine University, Düsseldorf; Department of Neurology (C.W.), University Hospital Cologne; Institute of Neuroimmunology and Multiple Sclerosis (M.A.F), University Medical Centre Hamburg-Eppendorf, Hamburg; NeuroCure Clinical Research Center (F.P.), Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin; Berlin Institute of Health and Experimental and Clinical Research Center (F.P.), Max Delbrück Center for Molecular Medicine and Charité—Universitätsmedizin Berlin; and Center of Neuroimmunology (B.T.), Philipps-University Marburg; and Munich Cluster for Systems Neurology (SyNergy) (B.H.), Germany.
- Correspondence
Dr. Hemmer hemmer{at}tum.de
Article usage
Cited By...
Letters: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.